Peptide vaccine for URLC10

Phase 1Vaccine

AAkita University Hospital

Peptide vaccine for URLC10 is one of 26 biologic programs targeting Bile Duct Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bile Duct CancerActive, not recruiting

Bile Duct CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Bile Duct Cancer

#DrugCompanyPhaseTrials

Stivarga

Bayer

Approved

—2

Photofrin

PPinnacle Biologics Inc.

Ixempra

Gemzar

2 5

Koselugo

AstraZeneca

Phase 2

1 6

Keytruda

Merck & Co.

Phase 2

1 7

Abraxane

Bristol-Myers Squibb

Phase 2

1 8

Lynparza

AstraZeneca

Phase 2

1 9

Imfinzi

Taxol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bile Duct Cancer1 trial

Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer

Suspended·—·Phase 1·NCT00624182·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Peptide vaccine for URLC10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peptide vaccine for URLC10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peptide vaccine for URLC10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Akita University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: AAkita University Hospital

Peptide vaccine for URLC10

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bile Duct Cancer1 trial

References

Drug Info

Quick Facts

Related News